Altay develops disease-modifying therapies targeting transcription…
Altay Therapeutics is a biopharmaceutical company dedicated to innovating therapeutic solutions for unmet medical needs, focusing particularly on the development of transcription factor inhibitors. The company's pipeline includes the first oral small molecule inhibitor of DUX4, aimed at treating facioscapulohumeral muscular dystrophy (FSHD), as well as a STAT3 inhibitor that targets cancer and chronic inflammatory diseases. Altay's approach is rooted in precision biology, aiming to provide novel therapeutic options for patients with limited treatment alternatives.
The core of Altay's technolo…